Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 7/20 | 0.58 |
| ▸ | LIMK2 | P53671 | 9/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3164258 | 0.90 | SCN3A (0.69) | SCN3ALIMK2LIMK1ABL1LCK | |
| SCHEMBL3163243 | 0.83 | SCN3A (0.80) | SCN3ASCN9ASCN5A | |
| SCHEMBL3162458 | 0.82 | SCN3A (0.69) | SCN3ASCN9ASCN5A | |
| SCHEMBL3058171 | 0.81 | SCN3A (0.64) | SCN3ASCN9ASCN5A | |
| SCHEMBL3068460 | 0.79 | SCN3A (0.77) | SCN3ASCN9ASCN5A | |
| SCHEMBL3160303 | 0.79 | SCN3A (0.64) | SCN3ARXFP1SCN9ASCN5A | |
| SCHEMBL3065605 | 0.78 | SCN3A (0.70) | SCN3ASCN9ASCN5A | |
| SCHEMBL13212119 | 0.77 | KMT2A (0.67) | SCN3ARXFP1 | |
| SCHEMBL3162519 | 0.75 | SCN3A (0.63) | SCN3ALIMK2LIMK1ABL1LCK | |
| SCHEMBL3169451 | 0.75 | SCN3A (0.61) | SCN3ASCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | SCN3A 13/4885LIMK2 2137/4885LIMK1 3310/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | SCN3A 13/4885LIMK2 2137/4885LIMK1 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.